Chongqing Zhifei Bio Products
Chongqing Zhifei Biological Products Co., Ltd. engages in the research and development, production, marketing, distribution, import, and export of vaccines in China. The company offers Recombinant Novel Coronavirus Vaccine (CHO Cell); Recombinant Mycobacterium Tuberculosis Fusion Protein under the Ekear brand; Haemophilus Influenzae Type b Vaccine under the XiFeiBei brand; ACYW135 Meningococcal P… Read more
Chongqing Zhifei Bio Products - Asset Resilience Ratio
Chongqing Zhifei Bio Products (300122) has an Asset Resilience Ratio of -0.08% as of September 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2014–2022)
This chart shows how Chongqing Zhifei Bio Products's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Chongqing Zhifei Bio Products's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥-41.38 Million | -0.08% |
| Total Liquid Assets | CN¥-41.38 Million | -0.08% |
Asset Resilience Insights
- Limited Liquidity: Chongqing Zhifei Bio Products maintains only -0.08% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
Chongqing Zhifei Bio Products Industry Peers by Asset Resilience Ratio
Compare Chongqing Zhifei Bio Products's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
MedPacto Inc
KQ:235980 |
Biotechnology | 49.82% |
|
Shenzhen CAU Technology Co Ltd
SHE:000004 |
Biotechnology | 6.20% |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403 |
Biotechnology | 6.88% |
|
Nanhua Bio Medicine Co Ltd
SHE:000504 |
Biotechnology | 11.93% |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518 |
Biotechnology | 0.03% |
|
Chengzhi Shareholding Co Ltd
SHE:000990 |
Biotechnology | 6.73% |
|
Hualan Biological EngineeringInc
SHE:002007 |
Biotechnology | 14.68% |
|
Da An Gene Co Ltd of Sun Yat-Sen University
SHE:002030 |
Biotechnology | 4.35% |
Annual Asset Resilience Ratio for Chongqing Zhifei Bio Products (2014–2022)
The table below shows the annual Asset Resilience Ratio data for Chongqing Zhifei Bio Products.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2022-12-31 | -0.03% | CN¥-10.15 Million | CN¥38.00 Billion | +0.14pp |
| 2021-12-31 | -0.17% | CN¥-51.45 Million | CN¥30.05 Billion | +0.15pp |
| 2020-12-31 | -0.32% | CN¥-49.19 Million | CN¥15.22 Billion | -0.08pp |
| 2019-12-31 | -0.25% | CN¥-27.11 Million | CN¥10.94 Billion | +0.24pp |
| 2018-12-31 | -0.49% | CN¥-33.04 Million | CN¥6.81 Billion | -0.38pp |
| 2017-12-31 | -0.11% | CN¥-4.41 Million | CN¥4.11 Billion | +0.14pp |
| 2016-12-31 | -0.25% | CN¥-6.76 Million | CN¥2.71 Billion | -0.28pp |
| 2015-12-31 | 0.03% | CN¥782.09K | CN¥2.68 Billion | +0.39pp |
| 2014-12-31 | -0.36% | CN¥-9.72 Million | CN¥2.71 Billion | -- |